Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial

医学 内科学 临床终点 卡铂 化疗 肺癌 不利影响 肿瘤科 完全响应 临床试验 新辅助治疗 阶段(地层学) 进行性疾病 外科 癌症 顺铂 乳腺癌 古生物学 生物
作者
Xinsheng Zhu,Liangdong Sun,Nan Song,Wenxin He,Boxiong Xie,Junjie Hu,Jing Zhang,Jie Yang,Jie Dai,Dongliang Bian,Haoran Xia,Fenghuan Sun,Anwen Xiong,Jie Luo,Lele Zhang,Huansha Yu,Ming Liu,Hongcheng Liu,Haifeng Wang,Haiping Zhang
出处
期刊:BMC Medicine [BioMed Central]
卷期号:20 (1): 493-493 被引量:65
标识
DOI:10.1186/s12916-022-02696-4
摘要

BACKGROUND: This trial aimed to analyse the safety, effectiveness and transcriptomic characteristics of neoadjuvant toripalimab plus chemotherapy in II-III non-small-cell lung cancer (NSCLC). METHODS: Patient eligibility mainly involved treatment-naive, clinical stage II-III and wild-type EGFR/ALK NSCLC. The patients received 2-4 cycles of toripalimab (240 mg q3w) plus carboplatin-based chemotherapy. After the second treatment cycle, all patients were re-evaluated by a multidisciplinary team. Candidates eligible for surgery underwent surgery; otherwise, patients received the remaining treatment cycles. The primary endpoints were safety and major pathological response (MPR). Secondary endpoints were R0 resection rate, progression-free survival (PFS) and overall survival (OS). RNA sequencing of baseline and post-treatment samples was conducted to explore the transcriptomic characteristics of the therapeutic response. RESULTS: In total, 50 eligible patients were enrolled, including 12 (24.0%) with resectable disease (RD) and 38 (76.0%) with potentially resectable disease (PRD). Treatment-related adverse events (TRAEs) were recorded in 48 cases (96.0%). Severe TRAEs occurred in 3 (6.0%) cases, including myelosuppression, drug-induced liver injury and death related to haemoptysis. The objective response rate (ORR) was 76.0%, with 8 (16.0%) patients having a complete response (CR), 30 (60.0%) partial response (PR), 10 (20.0%) stable disease (SD) and 2 (4.0%) progressive disease (PD). Surgery could be achieved in 12 (100%) patients with RD and 25 (65.8%) with PRD; 1 (2.0%) with PRD refused surgery. Therefore, R0 resection was performed for all 36 (100%) patients who underwent surgery; 20 (55.6%) achieved MPR, including 10 (27.8%) with a complete pathological response (pCR). The CHI3L1 (chitinase-3-like protein 1) immunohistochemistry (IHC) expression of baseline tumour samples could predict the therapeutic response (AUC=0.732), OS (P=0.017) and PFS (P=0.001). Increased PD-1 expression, T cell abundance and immune-related pathway enrichment were observed in post-treatment samples compared to baseline in the response group (CR+PR) but not in the non-response group (SD+PD). CONCLUSIONS: Neoadjuvant toripalimab plus chemotherapy was safe and effective, with a high MPR and manageable TRAEs for II-III NSCLC, even converting initially PRD to RD. Disparate transcriptomic characteristics of therapeutic efficiency were observed, and CHI3L1 expression predicted therapeutic response and survival. TRIAL REGISTRATION: ChiCTR1900024014, June 22, 2019.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
吃西瓜不吐籽完成签到 ,获得积分10
1秒前
elysia发布了新的文献求助10
1秒前
1秒前
六月雪发布了新的文献求助10
2秒前
所所的应助被lzh采纳,获得10
2秒前
林正心完成签到,获得积分10
3秒前
奇思妙想安德鲁完成签到,获得积分10
4秒前
顾矜的应助被热情的乐荷采纳,获得10
5秒前
9202211125完成签到,获得积分10
5秒前
郭夹心发布了新的文献求助10
5秒前
Akim的应助被一期一会采纳,获得10
5秒前
hmh发布了新的文献求助15
5秒前
水煮电吹风的应助被00hello00采纳,获得10
5秒前
6秒前
drfwjuikesv发布了新的文献求助10
6秒前
7秒前
一米阳光发布了新的文献求助10
7秒前
香蕉觅云的应助被Besttin9799采纳,获得30
7秒前
刘白完成签到,获得积分10
7秒前
Tracy发布了新的文献求助10
7秒前
LIUDAN发布了新的文献求助10
8秒前
9秒前
dieeee完成签到,获得积分10
10秒前
TaoJ的应助被ku采纳,获得10
11秒前
平淡的凌寒完成签到,获得积分10
11秒前
温柔发卡发布了新的文献求助10
11秒前
...完成签到,获得积分10
12秒前
哈基米德发布了新的文献求助10
13秒前
朴实的哲瀚完成签到 ,获得积分20
13秒前
展望未来完成签到 ,获得积分10
15秒前
16秒前
16秒前
小白菜完成签到,获得积分10
17秒前
一个橡果完成签到,获得积分10
17秒前
19秒前
poison完成签到 ,获得积分10
19秒前
19秒前
山海不远发布了新的文献求助30
20秒前
星辰大海的应助被哈基米德采纳,获得10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183667
求助须知:如何正确求助?哪些是违规求助? 9572953
关于积分的说明 21828185
捐赠科研通 7780853
什么是DOI,文献DOI怎么找? 3434031
关于科研通互助平台的介绍 2558251
邀请新用户注册赠送积分活动 2480500